Вы и ваши гормоны. Наука о женском здоровье и гормональной контрацепции

186. Krishnakumar, D., Hamblin, M. R., & Lakshmanan, S. (2015). Meditation and yoga can modulate brain mechanisms that affect behavior and anxiety: A modern scientific perspective. Ancient Science, 2(1), 13. doi:10.14259/­as.­v2i1.­171.

187. Morrell, M. J. (1999). Epilepsy in women: The science of why it is special. Neurology, 53(4), S42–S48; Majewska, M. D. (1987). Steroids and brain activity: Essential dialogue between body and mind. Biochemical Pharmacology, 36, 3781–3788.

188. Follesa, P., Porcu, P., Sogliano, C. et al. (2002). Changes in GABAA receptor γ2 subunit gene expression induced by long-term administration of oral contraceptives in rats. Neuropharmacology, 42(3), 325–336. doi:10.1016/s0028-3908(01)00187-3; Rapkin, A. J., Biggio, G., & Concas, A. (2006). Oral contraceptives and neuroactive steroids. Pharmacology Biochemistry and Behavior, 84(4), 628–634. doi:10.1016/­j.pbb.­2006.­06.­008.

189. Follesa, P., Porcu, P., Sogliano, C. et al. (2002). Changes in GABAA receptor γ2 subunit gene expression induced by long-term administration of oral contraceptives in rats. Neuropharmacology, 42(3), 325–336. doi:10.1016/­s0028-3908­(01)­001­87-3.

190. Paoletti, A. M., Lello, S., Fratta, S. et al. (2004). Psychological effect of the oral contraceptive formulation containing 3 mg of drospirenone plus 30 μg of ethinyl estradiol. Fertility and Sterility, 81(3), 645–651. doi:10.1016/­j.fertnstert.­2003.­08.­030; Rapkin, A. J., Biggio, G., & Concas, A. (2006). Oral contraceptives and neuroactive steroids. Pharmacology Biochemistry and Behavior, 84(4), 628–634. doi:10.1016/­j.pbb.­2006.­06.­00.

191. Follesa, P., Porcu, P., Sogliano, C. et al. (2002). Changes in GABAA receptor γ2 subunit gene expression induced by long-term administration of oral contraceptives in rats. Neuropharmacology, 42(3), 325–336. doi:10.1016/­s0028-3908­(01)­00187-3.

192. Hasler, G., Veen, J. W., Geraci, M.et al. (2009). Prefrontal cortical gamma-aminobutyric acid levels in panic disorder determined by proton magnetic resonance spectroscopy. Biological Psychiatry, 65(3), 273–275. doi:10.1016/­j.biopsych.­2008.­06.­023.

193. Brambilla, P., Perez, J., Barale, F. et al. (2003). GABAergic dysfunction in mood disorders. Molecular Psychiatry, 8(8), 715–715. doi:10.1038/­sj.­mp.­4001­395.

194. Petty, F., & Sherman, A. (1984). Plasma GABA levels in psychiatric illness. Journal of Affective Disorders, 6(2), 131–138. doi:10.1016/­0165-0327(84)90018-1; Petty, F., Kramer, G. L., Dunnam, D., & Rush, A. J. (1990). Plasma GABA in mood disorders. Psychopharmacology Bulletin, 26(2), 157–161; Petty, F., Kramer, G. L., Fulton, M. et al. (1993). Low plasma GABA is a trait-like marker for bipolar illness. Neuropsychopharmacology, 9(2), 125–132. doi:10.1038/­npp.­1993.­51.

195. Halbreich, U., Petty, F., Yonkers, K. et al. (1996). Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder. American Journal of Psychiatry, 153(5), 718–720. doi:10.1176/­ajp.­153.­5.718.

196. Petty, F., Fulton, M., Moeller, F. G., Kramer, G. et al. (1993). Plasma gamma-aminobutyric acid (GABA) is low in alcoholics. Psychopharmacology Bulletin, 29, 277–281.

197. Grant, B. F., Chou, S. P., Saha, T. D. et al. (2017). Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV Alcohol use disorder in the United States, 2001-2002 to 2012-2013: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry, 74(9): 911–923. doi:10.1001/­jama­psychiatry.­2017.­2161.